会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells
    • 鉴定用于预测与乳腺细胞相互作用和/或调节蛋白酪氨酸激酶和/或蛋白酪氨酸激酶途径的化合物的活性的多核苷酸
    • US20060029944A1
    • 2006-02-09
    • US11072175
    • 2005-03-04
    • Fei HuangXia HanKaren ReevesLukas AmlerCraig FairchildFrancis LeePeter Shaw
    • Fei HuangXia HanKaren ReevesLukas AmlerCraig FairchildFrancis LeePeter Shaw
    • C12Q1/68C07H21/04
    • C07K14/47A61K38/00C12Q1/6886C12Q2600/106C12Q2600/136C12Q2600/158
    • The present invention describes polynucleotides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., breast cell lines, to treatment with compounds that interact with and modulate, e.g., inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Eph receptors. These polynucleotides have been shown, through a weighted voting cross validation program, to have utility in predicting the resistance and sensitivity of breast cell lines to the compounds. The expression level or phosphorylation status of some polynucleotides is regulated by treatment with a particular protein tyrosine kinase inhibitor compound, thus indicating that these polynucleotides are involved in the protein tyrosine kinase signal transduction pathway, e.g., Src tyrosine kinase. Such polynucleotides, whose expression levels correlate highly with drug sensitivity or resistance and which are modulated by treatment with the compounds, comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., breast cancer, in which signaling through the protein tyrosine kinase pathway, such as the Src tyrosine kinase pathway, is involved with the disease process.
    • 本发明描述了已被发现与多种细胞相关的细胞(例如,乳腺细胞系)与用蛋白酪氨酸激酶相互作用并调节,例如抑制蛋白质酪氨酸激酶(例如, ,Src家族酪氨酸激酶的成员,例如Src,Fgr,Fyn,是,Blk,Hck,Lck和Lyn,以及其它蛋白酪氨酸激酶,包括Bcr-abl,Jak,PDGFR,c-kit和 Eph受体。 已经通过加权投票交叉验证程序显示了这些多核苷酸可用于预测乳腺细胞系对化合物的抵抗力和敏感性。 一些多核苷酸的表达水平或磷酸化状态通过用特定蛋白质酪氨酸激酶抑制剂化合物的处理来调节,从而表明这些多核苷酸参与蛋白酪氨酸激酶信号转导途径,例如Src酪氨酸激酶。 这些多核苷酸的表达水平与药物敏感性或抗性高度相关并且通过用化合物处理而被调节的多核苷酸包括用于预测药物反应的方法中的多核苷酸预测物或标志物组,以及疾病管理中的预后或诊断指标,特别是在那些 疾病领域,例如乳腺癌,其中通过蛋白酪氨酸激酶途径的信号传导,例如Src酪氨酸激酶途径参与疾病过程。